Rational design of potential Bcr-Abl tyrosine kinase inhibitors by the methods of molecular modeling

A. M. Andrianov ; Yu. V. Kornoushenko ; A. D. Karpenko ; I. P. Bosko ; Zh. V. Ignatovich ; E. V. Koroleva

Matematičeskaâ biologiâ i bioinformatika, Tome 15 (2020) no. 2, pp. 396-415.

Résumé

Discovery of the nature of inhibiting cancer processes by small organic molecules has changed the principles of the development of drug compounds for antitumor therapy. Recent achievements in this area are associated with the design of small-molecule protein kinase inhibitors, organic compounds exhibiting directed pathogenetic action. In this study, in silico design of 38 potential anti-cancer compounds with multikinase profile was carried out based on the derivatives of 2-arylaminopyrimidine. Evaluation of inhibitory activity potential of these compounds against the native and mutant (T$_{315I}$) forms of Bcr-Abl tyrosine kinase, an enzyme that plays a key role in the pathogenesis of chronic myeloid leukemia characterized by uncontrolled growth myeloid cells in peripheral blood and bone marrow, was performed using molecular modeling tools. As a result, 5 top-ranking compounds that exhibit, according to the calculated data, a high-affinity binding to the native and mutant Bcr-Abl tyrosine kinase were identified. The designed compounds were shown to form good scaffolds for the development of novel potent antitumor drugs.

Bibliographie

[1] W. J. Köstler, C. C. Zielinski, “Targeting Receptor Tyrosine Kinases in Cancer”, Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease, eds. D. L. Wheeler, Y. Yarden, Springer Science Business Media, New York, 2015, 78–225

[2] G. Maurer, B. Tarkowski, M. Baccarini, “Raf kinases in cancer-roles and therapeutic opportunities”, Oncogene, 30 (2011), 3477–3488 | DOI

[3] A. Bardelli, D. W. Parsons, N. Silliman, J. Ptak, S. Szabo, S. Saha, S. Markowitz, J. K.V. Willson, G. Parmigiani, K. W. Kinzler, B. Vogelstein, V. E. Velculescu, “Mutational analysis of the tyrosine kinome in colorectal cancers”, Science, 300:5621 (2003), 949 | DOI

[4] C. R. Bartram, A. de Klein, A. Hagemeijer, T. van Agthoven, A. Geurts van Kessel, D. Bootsma, G. Grosveld, M. A. Ferguson-Smith, T. Davies, M. Stone et al, “Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia”, Nature, 306 (1983), 277–280 | DOI

[5] P. A. Futreal, L. Coin, M. Marshall, T. Down, T. Hubbard, R. Wooster, N. Rahman, M. R. Stratton, “A census of human cancer genes”, Nat. Rev. Cancer, 4 (2004), 177–183 | DOI

[6] H. Kittler, P. Tschand, “Driver mutations in the mitogen-activated protein kinase pathway: the seeds of good and evil”, Br. J. Dermat., 178 (2018), 26–27 | DOI

[7] S. Sato, H. Sanjo, K. Takeda, J. Ninomiya-Tsuji, M. Yamamoto, T. Kawai, K. Matsumoto, O. Takeuchi, S. Akira, “Essential function for the kinase TAK1 in innate and adaptive immune responses”, Nat. Immunol., 6:11 (2005), 1087–1095 | DOI

[8] B. K. Mueller, H. Mack, N. Teusch, “Rho kinase, a promising drug target for neurological disorders”, Nat. Rev. Drug. Discov., 4 (2005), 98–387 | DOI

[9] Z. Z. Chong, Y. C. Shang, S. Wang, K. Maiese, “A critical kinase cascade in neurological disorders: PI 3-K, Akt and Mtor”, Future Neurol, 7 (2012), 733–748 | DOI

[10] C. E. Tabit, S. M. Shenouda, M. Holbrook, J. L. Fetterman, S. Kiani, A. A. Frame, M. A. Kluge, A. Held, M. M. Dohadwala, N. Gokce, M. G. Farb, J. Rosenzweig, N. Ruderman, J. A. Vita, N. M. Hamburg, “Protein kinase C-$\beta$ contributes to impaired endothelial insulin signaling in humans with diabetes mellitus”, Circulation, 127 (2013), 86–95 | DOI

[11] K. S. Bhullar, N. O. Lagarón, E. M. McGowan, I. Parmar, A. Jha, B. P. Hubbard, H. P. V. Rupasinghe, “Kinase-targeted cancer therapies: progress, challenges and future directions”, Mol. Cancer, 17 (2018), 48 | DOI

[12] A. C. Dar, K. M. Shokat, “The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling”, Annu. Rev. Biochem., 80 (2011), 769–795 | DOI

[13] R. Roskoski, “Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes”, Pharmacol. Res., 103 (2016), 26–48 | DOI

[14] H. Kantarjian, C. Sawyers, A. Hochhaus, F. Guilhot, C. Schiffer, C. Gambacorti-Passerini, D. Niederwieser, D. Resta, R. Capdeville, U. Zoellner et al, “Hematologic and cytogenetic responses to imatinib mesylate in chronic leukemia”, New Engl. J. Med., 346 (2002), 645–652 | DOI

[15] “Imatinib. New indications, but not robust evidence”, Prescrire Int., 95 (2008), 91–94

[16] S. G. O'Brien, F. Guilhot, R. A. Larson, I. Gathmann, M. Baccarani, F. Cervantes, J. J. Cornelissen, T. Fischer, A. Hochhaus, T. Hughes et al, “IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia”, New Engl. J. Med., 348 (2003), 994–1004 | DOI

[17] B. J. Druker, F. Guilhot, S. G. O'Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M. W.N. Deininger, R. T. Silver, J. M. Goldman, R. M. Stone et al, “Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia”, New Engl. J. Med., 355 (2006), 2408–2417 | DOI

[18] A. Hochhaus, R. A. Larson, F. Guilhot, J. P. Radich, S. Branford, T. P. Hughes, M. Baccarani, M. W. Deininger, F. Cervantes, S. Fujihara et al, “Long-term outcomes of imatinib treatment for chronic myeloid leukemia”, New Engl. J. Med, 376:10 (2017), 917–927 | DOI

[19] N. P. Shah, C. Tran, F. Y. Lee, P. Chen, D. Norris, C. L. Sawyers, “Overriding imatinib resistance with a novel ABL kinase inhibitor”, Science, 305:5682 (2004), 399–401 | DOI

[20] L. J. Lombardo, F. Y. Lee, P. Chen, D. Norris, J. C. Barrish, K. Behnia, S. Castaneda, L. A.M. Cornelius, J. Das, A. M. Doweyko et al, “Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays”, J. Med. Chem., 47:27 (2004), 6658–6661 | DOI

[21] A. Hochhaus, R. A. Larson, F. Guilhot, J. P. Radich, S. Branford, T. P. Hughes, M. Baccarani, M. W. Deininger, F. Cervantes, S. Fujihara et al, “Long-term outcomes of imatinib treatment for chronic myeloid leukemia”, N. Engl. J. Med., 376 (2017), 917–927 | DOI

[22] S. Davies, H. Reddy, M. Caivano, P. Cohen, “Specificity and mechanism of action of some commonly used protein kinase inhibitors”, Biochem. J., 351 (2000), 95–105 | DOI

[23] T. O'Hare, “A decade of nilotinib and dasatinib: From in vitro studies to first-line tyrosine kinase inhibitors”, Cancer Res., 76:20 (2016), 5911–5913 | DOI

[24] G. Saglio, D. W. Kim, S. Issaragrisil, P. le Coutre, G. Etienne, C. Lobo, R. Pasquini, R. E. Clark, A. Hochhaus, T. P. Hughes et al, “Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia”, New Engl. J. Med., 362:24 (2010), 2251–2259 | DOI

[25] H. M. Kantarjian, A. Hochhaus, G. Saglio, C. De Souza, I. W. Flinn, L. Stenke, Y. T. Goh, G. Rosti, H. Nakamae, N. J. Gallagher et al, “Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial”, The Lancet Oncol, 12:9 (2011), 841–851 | DOI

[26] F. H. Tan, T. L. Putoczki, S. S. Stylli, R. B. Luwor, “Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies”, OncoTargets Ther., 12 (2019), 635–645 | DOI

[27] J. H. Lipton, C. Chuah, A. Guerci-Bresler, G. Rosti, D. Simpson, S. Assouline, G. Etienne et al, “Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: An international, randomised, open-label, phase 3 trial”, The Lancet Oncol., 17:5 (2016), 612–621 | DOI

[28] D. Wang, H. Pan, Y. Wang, “T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib”, Leuk. Lymphoma, 58:7 (2017), 1733–1735 | DOI

[29] H. M. Kantarjian, J. E. Cortes, D. W. Kim, H. J. Khoury, T. H. Brümmendorf, K. Porkka, G. Martinelli, S. Durrant, E. Leip, V. Kelly et al, “Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors”, Blood, 123:9 (2014), 1309–1318 | DOI

[30] J. E. Cortes, D. W. Kim, H. M. Kantarjian, T. H. Brümmendorf, I. Dyagil, L. Griskevicius, H. Malhotra, C. Powell, K. Gogat, A. M. Countouriotis, C. J. Gambacorti-Passerini, “Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial”, Clin. Oncol., 30:28 (2012), 3486–3492 | DOI

[31] Brümmendorf T.H., Cortes J.E., de Souza C.A., Guilhot F., Duvillié L., Pavlov D., Gogat K., Countouriotis A.M., Gambacorti-Passerini C., “Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: Results from the 24-month follow-up of the BELA trial”, Br. J. Haematol., 168:1 (2015), 69–81 | DOI

[32] Kantarjian H.M., Cortes J.E., Kim D.W., Khoury H.J., Brümmendorf T.H., Porkka K., Martinelli G., Durrant S., Leip E., Kelly V., Turnbull K., Besson N., Gambacorti-Passerini C., “Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors”, Blood, 123:9 (2014), 1309–1318 | DOI

[33] J. J.P. Stewart, “Optimization of parameters for semiempirical methods VI: more modifications to the NDDO approximations and re-optimization of parameters”, J. Mol. Model, 19 (2013), 1–32 | DOI

[34] K. R. Cousins, “Computer review of ChemDraw Ultra 12.0”, J. Am. Chem. Soc., 133:21 (2011), 8388 | DOI

[35] Open Babel: The Open Source Chemistry Toolbox, (accessed 02.12.2020) http://openbabel.org/wiki/Main_Page

[36] A. K. Rappe, C. J. Casewit, K. S. Colwell, W. A. Goddard III, W. M. Skiff, “UFF, a full periodic table force field for molecular mechanics and molecular dynamics simulations”, J. Am. Chem. Soc., 114:25 (1992), 10024–10035 | DOI

[37] A. Alhossary, S. D. Handoko, Y. Mu, C. K. Kwoh, “Fast, accurate, and reliable molecular docking with QuickVina 2”, Bioinformatics, 31:13 (2015), 2214–2216 | DOI

[38] T. Zhou, L. Commodore, W. S. Huang, Y. Wang, M. Thomas, J. Keats, Q. Xu, V. M. Rivera, W. C. Shakespeare, T. Clackson et al, “Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): Lessons for overcoming kinase inhibitor resistance”, Chem. Biol. Drug Des., 77:1 (2011), 1–11 | DOI

[39] M. A. Seeliger, B. Nagar, F. Frank, X. Cao, M. N. Henderson, J. Kuriyan, “C-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty”, Structure, 15:3 (2007), 299–311 | DOI | MR

[40] E. Weisberg, P. W. Manley, W. Breitenstein, J. Brueggen, S. W. Cowan-Jacob, A. Ray, B. Huntly, D. Fabbro, G. Fendrich, E. Hall-Meyers, A. L. Kung, J. Mestan, G. Q. Daley, L. Callahan, L. Catley, C. Cavazza, M. Azam, D. Neuberg, R. D. Wright, D. G. Gilliland, J. D. Griffin, “Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl”, Cancer Cell, 7:2 (2005), 129–141 | DOI

[41] J. S. Tokarski, J. Newitt, C. Y.J. Chang, J. D. Cheng, M. Wittekind, S. E. Kiefer, K. Kish, F. Y.F. Lee, R. Borzilerri, L. J. Lombardo, D. Xie, Y. Zhang, H. E. Klei, “The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants”, Cancer Res, 66 (2006), 5790–5797 | DOI

[42] T. Horio, T. Hamasaki, T. Inoue, T. Wakayama, S. Itou, H. Naito, T. Asaki, H. Hayase, T. Niwa, “Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives”, Bioorg. Med. Chem. Lett, 17 (2007), 2712–2717 | DOI

[43] J. J.P. Stewart, MOPAC2016, Stewart Computational Chemistry, Colorado Springs, Google Scholar, 2016

[44] A. Klamt, G. J. Schüürmann, “COSMO: a new approach to dielectric screening in solvents with explicit expressions for the screening energy and its gradient”, Chem. Soc. Perkin Trans., 2 (1993), 799–805 | DOI

[45] I. M. Høyvik, B. Jansik, P. Jørgensen, “Trust region minimization of orbital localization functions”, J. Chem. Theory Comput., 8 (2012), 3137–3146 | DOI

[46] D. A. Case, K. Belfon, I. Y. Ben-Shalom, S. R. Brozell, D. S. Cerutti, T. E. Cheatham III, V. W.D. Cruzeiro, T. A. Darden, R. E. Duke, G. Giambasu et al, AMBER 2020, University of California, San Francisco, 2020

[47] J. Wang, R. M. Wolf, J. W. Caldwell, P. A. Kollman, D. A. Case, “Development and testing of a general Amber force field”, J. Comput. Chem., 25 (2004), 1157–1174 | DOI

[48] W. L. Jorgensen, J. Chandrasekhar, J. D. Madura, R. W. Impey, M. L. Klein, “Comparison of simple potential functions for simulating liquid water”, J. Chem. Phys., 79:2 (1983), 926–935 | DOI

[49] J. P. Ryckaert, G. Ciccotti, H. J.C. Berendsen, “Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes”, J. Comput. Phys., 23:3 (1977), 327–341 | DOI

[50] U. Essmann, L. Perera, M. L. Berkowitz, T. Darden, H. Lee, L. G. Pedersen, “A smooth particle mesh Ewald method”, J. Chem. Phys., 103 (1995), 8577–8593 | DOI

[51] J. D. Durrant, J. A. McCammon, “BINANA: A novel algorithm for ligand-binding characterization”, J. Mol. Graph. Model, 29:6 (2011), 888–893 | DOI

[52] E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng, T. E. Ferrin, “UCSF Chimera a visualization system for exploratory research and analysis”, J. Comput. Chem., 25:13 (2004), 1605–1612 | DOI

[53] I. K. McDonald, J. M. Thornton, “Satisfying hydrogen bonding potential in proteins”, J. Mol. Biol., 238:5 (1994), 777–793 | DOI

[54] J. D. Durrant, J. A. McCammon, “NNScore 2.0: A neural-network receptor-ligand scoring function”, J. Chem. Inf. Model., 51:11 (2011), 2897–2903 | DOI

[55] G. Sharma, E. A. First, “Thermodynamic analysis reveals a temperature-dependent change in the catalytic mechanism of Bacillus stearothermophilus tyrosyl-tRNA synthetase”, J. Biol. Chem., 284:7 (2009), 4179–4190 | DOI

[56] S. Genheden, U. Ryde, “The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinity”, Expert Opin. Drug Discov., 10:5 (2015), 449–461 | DOI

[57] L. Xu, H. Sun, Y. Li, J. Wang, T. Hou, “Assessing the performance of MM/PBSA and MM/GBSA methods. 3. The impact of force fields and ligand charge models”, J. Phys. Chem. B, 117:28 (2013), 8408–8421 | DOI

[58] H. Sun, Y. Li, S. Tian, L. Xu, T. Hou, “Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set”, Phys. Chem. Chem. Phys., 16 (2014), 16719–16729 | DOI

[59] C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, “Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings”, Adv. Drug Del. Rev., 46:1–3 (2001), 11259830, 3–26 | DOI

[60] A. S. Christensen, T. Kubař, Q. Cui, M. Elstner, “Semiempirical quantum mechanical methods for noncovalent interactions for chemical and biochemical applications”, Chem. Rev., 116:9 (2016), 5301–5337 | DOI

[61] A. Cherkasov, E. N. Muratov, D. Fourches, A. Varnek, II. Baskin, M. Cronin, J. Dearden, P. Gramatica, Y. C. Martin, R. Todeschini, V. Consonni, V. E. Kuz'min, R. Cramer, R. Benigni, C. Yang, J. Rathman, L. Terfloth, J. Gasteiger, A. Richard, A. Tropsha, QSAR modeling: where have you been? Where are you going to?, J. Med. Chem., 57:12 (2014), 4977–5010 | DOI

[62] C. Kuseva, T. W. Schultz, D. Yordanova, K. Tankova, S. Kutsarova, T. Pavlov, A. Chapkanov, M. Georgiev, A. Gissi, T. Sobanski, O. G. Mekenyan, “The implementation of RAAF in the OECD QSAR Toolbox”, Reg. Toxicol. Pharmacol., 105 (2019), 51–61 | DOI